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Background. Mammographic screening is carried out at public sector hospitals as part of clinical practice. 
Objective. We report the experience of such screening at Tygerberg Academic Hospital (TBAH), a tertiary referral hospital in the Western 
Cape Province, South Africa.
Methods. All mammograms performed between 2003 and 2012 at TBAH were analysed regarding patient demographics, clinical data, 
indication and outcome according to the American College of Radiology Breast Imaging Reporting and Data System (BIRADS). Screening 
mammography was offered to patients >40 years of age and mammograms were read by experienced breast surgeons. Patients with BIRADS 
3 and 4 lesions were recalled for short-term follow-up, further imaging or tissue acquisition. Patients with BIRADS 5 lesions were recalled 
for tissue acquisition. Further imaging, method of tissue acquisition, histology results and use of neo-adjuvant therapy were also recorded. 
Results. Of 16 105 mammograms, 3 774 (23.4%) were carried out for screening purposes. The median age of patients undergoing screening 
was 54 years. Of 407 women with mammograms that were reported as BIRADS 3 - 5 (10.8% of screening mammograms), 187 (46% of 
recalled women) went on to have further imaging only. Tissue was acquired in 175 patients (43% of recalled women), comprising a biopsy 
rate of 4.6% of the total series. The malignancy rate in cases in which tissue acquisition was done was 25%. Forty-three breast cancers were 
diagnosed (11.4/1 000 examinations). Of the cancers, nine (31%) were ductal carcinomas in situ. Of 20 invasive cancers, nine (45%) were 
<10 mm in size. Of the invasive cancers, 40% were node-positive. 
Conclusions. The cancer diagnosis rate indicates a high breast cancer load in an urbanised population. 
S Afr Med J 2014;104(4):294-296. DOI:10.7196/SAMJ.7246
Mammographic screening for breast cancer 
in a resource-restricted environment
J P Apffelstaedt,1 Dr Med, MMed (Surg), FCS (SA), MBA; L Dalmayer,2 MB ChB; K Baatjes,1 MB ChB, MMed (Surgery), FCS (SA) 
1  Department of Surgery, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa
2  Department of Radiation Oncology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa
Corresponding author: J P Apffelstaedt (jpa@sun.ac.za)
RESEARCH
295       April 2014, Vol. 104, No. 4
Breast cancer is a growing healthcare burden, especially 
in the developing world.[1,2] Breast cancer is the most 
common female cancer in South Africa (SA) and 
accounts for 20% of all cancers diagnosed in women 
in SA.[3] Breast cancer constitutes the largest cancer-
related disease burden in women in the Western Cape (WC) Province, 
SA.[4] Because limited resources make mammographic breast screening 
difficult to implement, population screening for breast cancer is 
not part of WC health policy at present, and will not be within the 
foreseeable future.[5] Despite this, numerous screening mammograms 
are undertaken at public sector facilities as part of clinical practice. 
We report the results of such screening mammograms at an academic 
teaching hospital in the WC over a period of 9 years. 
Methods
All mammograms performed between 2003 and 2012 at Tygerberg 
Academic Hospital (TBAH), serving a mostly indigent population in 
Cape Town, were prospectively entered into MS Access. Data entered 
included basic patient demographic data such as age and gender, 
and clinical data such as use and duration of hormone replacement 
therapy, evidence of previous breast surgery on examination, 
indication and outcome. Screening mammography was offered to 
patients referred to the breast clinic who were ≥40 years of age and 
to younger patients with significant risk factors. Patients who had a 
palpable mass or personal history of breast cancer were excluded. If 
a diagnosis of malignancy was made, the tumour stage and detailed 
histopathological data were recorded, as well as treatment for the 
malignancy. Screening was classified as ‘prevalence’ if no prior 
mammography performed within the past 18 months was available 
for comparison, or ‘incidence’ if such imaging was available.
Initially, all mammograms were performed by certified 
mammographers, using a Senographe Mammography System 
(GE Healthcare, UK); later, a Giotto 6000 mammography system 
(Internazionale Medico Scientifica, Italy) was used. The film used 
was Mamoray HDR film (Agfa Corporation, USA). Films were 
developed on an Agfa Classic EOS developer. From 2009, computed 
radiography was employed and from March 2012, a full-field digital 
system (Siemens, Germany) was introduced. The views taken were 
standard craniocaudal and mediolateral oblique; additional views 
such as ‘Cleopatra’ views, spot compression and magnification views 
and ‘valley’ views were taken, as indicated.
The outcomes of the mammography were classified according to 
the American College of Radiology Breast Imaging Reporting and 
Data System (BIRADS).[6] Patients with BIRADS 3 and 4 lesions 
were recalled for short-term follow-up, further imaging or tissue 
acquisition. Patients with BIRADS 5 lesions were recalled for tissue 
acquisition. Further imaging, method of tissue acquisition, histology 
results and use of neo-adjuvant therapy were also recorded. Patients 
who failed to present for further work-up, despite contact by mail, 
were deemed ‘defaulters’.
Diagnosed cancers were staged according to the TNM clinical and 
pathological staging system.[7] 
Results
A total of 16  105 mammograms were performed between January 
2003 and May 2012, 3 774 (23.4%) for screening purposes. Of these, 
48% were classified as ‘prevalence’ and 52% as ‘incidence’ screening. 
The median age of women undergoing screening mammography was 
54 years; 32% of the women were 40 - 49 years of age. 
Of the screening mammograms, 3  367 (89.2%) were reported as 
BIRADS 1 and 2, 359 (9.5%) as BIRADS 3 and 4, and 48 (1.3%) as 
BIRADS 5. 
Of 407 recalled patients, who represented 10.8% of all women who 
had screening mammograms, 187 (46%) went on to have further 
imaging that was reported as benign. Tissue was acquired in 175 patients 
(43%), constituting a biopsy rate of 4.6% of the total series. Thirty-four 
Table 1. Comparison of the current series with global benchmark programmes
Criterion USA,[12] % NHS (UK),[13] % Breast Screen (Aus),[13,14] % Current series, %
Recall rate* 9.8 7.7 (prevalence) 
2.8 (incidence)
4 - 12 10.8
Biopsy rate* - 1.72 - 4.6
Malignancy rate of biopsies* 33.8 45.5 - 25
Cancers per age group (years)*
All 4.7 - - 11.4
40 - 49 - 7.8 (>45 years) 2.4 -
50 - 69  - - 12.1 (prevalence)
5.7 (incidence) 
-
In situ cancers (of total) 21.6 20.6 20.2 31
Invasive cancers, size (mm)
Of total 78.4 79.4 79.8 69
<10* 37.2 - - 45 
11 - 20* 31.6† 50.8 (<15 mm) 47 (prevalence)
63 (incidence ) (<15 mm)
20 
>20* 21.2† - - 30 
Node-negative* 79.8 76 - 60 
Node-positive* 20.2 24 - 40
USA = United States of America; NHS = National Health Service; UK = United Kingdom; Aus = Australia.
*Data combine incidence and prevalence rounds. 
†In 8.5% of invasive cancers, the size was unknown.
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recalled patients did not present for further work-up, in 4 patients work-
up was incomplete, 2 patients were found to have lymphoma, and 5 
patients died before a definitive diagnosis could be established. 
The biopsy rate in cases in which tissues acquisition was done for 
the whole series was 4.6%; the malignancy rate of tissue acquisition 
was 25%. Forty-three breast cancers were diagnosed, giving a cancer 
diagnosis rate of 11.4/1 000 examinations. Of the cancers, nine (31%) 
were ductal carcinomas in situ. Of 20 invasive cancers, 45% (in nine 
patients) were <10 mm in size and 40% were node-positive. Fourteen 
patients were excluded from further analysis: 7 failed to return for 
cancer treatment, 1 had metastatic disease, 2 received neo-adjuvant 
systemic therapy, and in 4 the work-up was incomplete at the close 
of the database. 
Discussion
A significant number of mammographic examinations in the 
public sector are for screening purposes and reflect adherence to 
good clinical practice. If surveillance mammography after a cancer 
diagnosis is included, about three-quarters of all mammographies 
in similar centres to TBAH will be done on asymptomatic women. 
This calls into question the frequently made distinction between 
symptomatic and screening mammography.[8] It is our contention 
that, as soon as a mammography unit is set up, the majority of 
examinations will be of asymptomatic women. This has important 
implications for resource allocation in that the required skills and 
technology must then be in place to address non-palpable lesions. 
The screening effort we report here is best described as 
‘opportunistic’ screening.[9] In contrast to organised screening, in 
opportunistic screening there are no generally agreed performance 
standards and women are not invited, but present of their own 
volition for what is sometimes unrelated pathology.[9] Reasons for 
requesting screening may include a family history of breast cancer, 
which often turns out to be non-significant, mastalgia, referral for a 
mass in the breast that cannot be verified at physical examination, or 
simple general concern about breast cancer risk. As such, it is possible 
to speculate that the breast cancer diagnosis rate would be higher in 
such a population than in an organised screening programme. 
A hallmark of opportunistic screening programmes is their wide 
variation in quality parameters.[9,10] Despite this, and with the caveat 
that small numbers do not permit definitive conclusions, the results 
described here are remarkably similar to those of major international 
organised screening programmes (Table 1), with the exception of the 
rate of node-negative invasive cancers. This latter warrants further 
exploration in a larger programme, especially as the invasive cancers 
were remarkably similar in size to those in the other programmes 
quoted. However, the age composition in our series was much younger, 
implying diagnosis of more aggressive cancers. Owing to small 
numbers, no attempt was made to differentiate between ‘prevalence’ 
and ‘incidence’ screening; this is commonly not done in reports of 
opportunistic screening efforts. 
Recently, much discussion has centred around ‘harms’ generated by 
mammographic screening, inter alia psychological distress caused by 
unnecessary recalls, physical harms caused by unnecessary biopsies and 
health system harms of resources diverted to screening. These potential 
‘harms’ have led to the controversially restrictive recommendations of 
the US Preventive Services Task Force for mammographic screening. [11] 
In this series, harms would have fallen within the parameters set by 
benchmark programmes and are indicative of the rigorous attention to 
quality at all steps of the diagnostic process. 
A much larger proportion (32%) of screened women in this series 
than in the benchmark organised screening programmes were in the 40 - 
49-year age group; in this age group, the cancer diagnosis rate is expected 
to be much lower than in the 50 - 69-year age group. Only 4.3% of the 
screened population in the UK National Health Service (NHS) screening 
programme and 14.3% in Breast Screen Australia were in this younger 
age group; in the US programme, where an ‘opportunistic’ approach 
was also followed, the proportion was 34.1%. Despite this, the cancer 
diagnosis rate in our TBAH series is as high as in known high-incidence 
populations. A reason for this may be the selection of patients from 
a largely symptomatic service; however, it fits with data from another 
centre in the same geographical area engaging mostly in screening 
examinations.[15] The high diagnosis rate calls into question the often 
quoted figure of a 1/28 lifetime risk of breast cancer in our population.[3] 
The TBAH screening figures are more in line with those of populations 
where the lifetime risk is ~1/8 - 1/10 women. 
A further noteworthy fact is that this TBAH series was based exclusively 
on mammography interpretation by surgeons with a special interest in 
breast health. Despite this, the results compare well with international 
benchmarks and signal that the desired early diagnosis of breast cancer 
was achieved. The well-documented shortage of radiologists, specifically 
breast radiologists,[15] must not prevent the urgent establishment of breast 
centres to cater for the rapidly rising disease burden of breast cancer 
in our country while there are trained and experienced surgeons, with 
a special interest in breast health, available to interpret breast imaging. 
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